Prognostic Factors of ICU Mortality in Pediatric Oncology Patients With Pulmonary Complications

J Pediatr Hematol Oncol. 2020 May;42(4):266-270. doi: 10.1097/MPH.0000000000001616.

Abstract

Objective: This study aimed to determine prognostic factors associated with mortality in pediatric oncology patients admitted to the intensive care unit (ICU) with pulmonary complications.

Materials and methods: This retrospective cohort study included patients 21 years of age with underlying oncologic diseases admitted to the ICU of a Korean Tertiary Referral Hospital with pulmonary complications from April 2009 to March 2017. Patients admitted for perioperative management or nonpulmonary complications were excluded. Demographic, laboratory, and clinical parameters (eg, Glasgow Coma Scale [GCS], pediatric Sequential Organ Failure Assessment [pSOFA], and Pediatric Logistic Organ Dysfunction [PELOD] scores) were reviewed.

Results: Overall, 110 patients (62 male, 56.3%) with a median age of 13 years (interquartile range: 8 to 16 y) were studied. The median ICU stay was 8 days (interquartile range: 4.25 to 16 d). Forty-five (40.9%) patients required mechanical ventilation. The overall mortality rate was 59.1% (65/110 patients). A multivariate logistic regression identified a low GCS score, peripheral oxygen saturation/fraction of inspired oxygen ratio, and hematocrit and increased total bilirubin as significantly associated with increased mortality. The pSOFA and PELOD scores on days 1 and 3 postadmission predicted in-ICU mortality, with corresponding areas under the curve of 0.80/0.76 and 0.87/0.83, respectively.

Conclusion: Several clinical scores and factors may predict mortality in pediatric oncology patients with pulmonary complications.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Disease-Free Survival
  • Female
  • Hospital Mortality*
  • Humans
  • Intensive Care Units*
  • Length of Stay*
  • Lung Diseases* / etiology
  • Lung Diseases* / mortality
  • Lung Diseases* / therapy
  • Male
  • Neoplasms* / mortality
  • Neoplasms* / therapy
  • Predictive Value of Tests
  • Retrospective Studies
  • Risk Factors
  • Survival Rate